Melina Marmarelis, MD, MSCE, is an assistant professor at the University of Pennsylvania and the Medical Director of the Penn Medicine Mesothelioma and Pleural Disease Program. She specializes in thoracic medical oncology. Her research focuses on early phase clinical trials in lung cancer and mesothelioma, determinants of therapy resistance and sensitivity, and molecular characteristics and testing in non-small cell lung cancer (NSCLC). She is the co-director of the Molecular Tumor Board at the University of Pennsylvania. Dr. Marmarelis earned her medical degree at Harvard Medical School. She completed her residency at Brigham and Women’s Hospital and Hematology/Oncology fellowship at the Hospital of the University of Pennsylvania. Dr. Marmarelis is board certified in internal medicine and medical oncology.
RET fusion-positive NSCLC: Informing on the use of pralsetinib for patients with RET fusion-positive, advanced NSCLC